Diagnosis, Prevention and Treatment of Stable COPD and Acute Exacerbations of COPD: The Swiss Recommendations 2018

Stolz, Daiana; Barandun, J; Borer, H; Bridevaux, Pierre‐Olivier; Brun, Patrick; Brutsche, Martin; Clarenbach, Christian F.; Eich, Christine; Fiechter, René; Frey, Martin; Geiser, Thomas; Grob, Michael; Helfenstein, Erich; Junker, Lilian; Kohler, Malcolm; Latshang, Tsogyal D.; A, Lechmann; Maurer, Marc; Nicod, Laurent; Quadri, Franco; Schilter, Daniel; Sigrist, Thomas; Soccal, Paola M.; Tarr, Philip E.; Thurnheer, Robert; Turk, Alexander; Tamm, Michael

doi:10.1159/000490551

Cited by 33 publications

(35 citation statements)

References 101 publications

(106 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nine CPGs (22%) included in the original sampling frame (2006–2016) have been updated (Table S2, Supplementary Materials) [50,51,52,53,54,55,56,57,58], and one new CPG was identified [59]. Within updated or newly identified CPGs, there were nine mentions of “pain”.…”

Section: Resultsmentioning

confidence: 99%

Systematic Review of Pain in Clinical Practice Guidelines for Management of COPD: A Case for Including Chronic Pain?

et al. 2019

View full text Add to dashboard Cite

Chronic pain is highly prevalent and more common in people with chronic obstructive pulmonary disease (COPD) than people of similar age/sex in the general population. This systematic review aimed to describe how frequently and in which contexts pain is considered in the clinical practice guidelines (CPGs) for the broad management of COPD. Databases (Medline, Scopus, CiNAHL, EMbase, and clinical guideline) and websites were searched to identify current versions of COPD CPGs published in any language since 2006. Data on the frequency, context, and specific recommendations or strategies for the assessment or management of pain were extracted, collated, and reported descriptively. Of the 41 CPGs (English n = 20) reviewed, 16 (39%) did not mention pain. Within the remaining 25 CPGs, pain was mentioned 67 times (ranging from 1 to 10 mentions in a single CPG). The most frequent contexts for mentioning pain were as a potential side effect of specific pharmacotherapies (22 mentions in 13 CPGs), as part of differential diagnosis (14 mentions in 10 CPGs), and end of life or palliative care management (7 mentions in 6 CPGs). In people with COPD, chronic pain is common; adversely impacts quality of life, mood, breathlessness, and participation in activities of daily living; and warrants consideration within CPGs for COPD.

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic Review of Pain in Clinical Practice Guidelines for Management of COPD: A Case for Including Chronic Pain?

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The pathological feature of COPD is complicated by chronic bronchitis, small airway fibrosis and emphysema [4,21]. To further investigate the role of Rcn3 in emphysema, the mouse model of emphysema by intra-trachea administration of PPE was used in the current study.…”

Section: Discussionmentioning

confidence: 99%

“…Chronic bronchitis and emphysema are the main pathological features of COPD [3]. Emphysema is characterized by the enlargement of air space and the destruction of the parenchymal structure leading to progressive airflow limitation [1,4]. The effective treatment for emphysema is limited, due to the insufficient knowledge regarding alveolar structural recovery and reconstruction in emphysema.…”

Section: Introductionmentioning

confidence: 99%

Suppression of Rcn3 in the alveolar epithelial cells may have beneficial effect against COPD

Zhang

Wang

Jin

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Chronic obstructive pulmonary disease (COPD) is a highly prevalent lung disease worldwide and imposes increasing disease burdens globally. COPD is characterized by irreversible airflow obstruction. Emphysema is one of the primary pathological features causing the irreversible decline of pulmonary function, while the precise mechanisms behind emphysema remain unclear. Reticulocalbin 3 (Rcn3) is an endoplasmic reticulum (ER) lumen protein localized in the secretory pathway of living cells. We have reported that Rcn3 in type II alveolar epithelial cell (AECIIs) plays a critical role in perinatal lung development and bleomycin-induced lung injury-repair. Since is associated with alveolar epithelial disruption, Rcn3 might be involved in the development of emphysema during COPD. Materials and Methods : We examined Rcn3 expression in lung specimens from patients (44 COPD patients and 26 non-COPD control patients) undergoing lung lobectomy or pneumonectomy. Mouse models of COPD and emphysema were established by cigarette smoke (CS) exposure and intratracheal installation of pancreatic porcine elastase (PPE), respectively. Rcn3 expression was detected in the lung tissues from these mice. Furthermore, conditional knockout (CKO) mice with Rcn3 deletion specific to AECIIs, were used to explore the role of Rcn3 in PPE-induced emphysema progression. Rcn3 protein expression in lung tissues were evaluated by Western blot and immunohistochemistry. Rcn3 mRNA expression in lung tissues was detected by qPCR.Results : Compared with non-COPD patients, Rcn3 expression was significantly increased in the lung specimens from COPD patients. Rcn3 expression was also significantly up-regulated in the lung tissues from COPD mice and emphysematous mice. Moreover, selective ablation of Rcn3 in AEC IIs significantly alleviated severity of the mouse emphysema in response to intratracheal installation of PPE.Conclusions: Our data, for the first time, indicated that Rcn3 in AECIIs might play a role in modulating the progression of emphysema, and thus be involved in the development of COPD. Suppression of Rcn3 expression in AECIIs may have a beneficial effect on COPD.This work was supported by National Natural Science Foundation of China (No. 81641004).

show abstract

“…Chronic obstructive pulmonary disease (COPD) is a disease characterized by incomplete reversibility of airflow obstruction, chronic inflammation of the airways, and systemic effects or comorbidities [1][2][3]. Although COPD is a preventable and treatable disease, it still brings heavy economic burden to family and the society [4][5][6]. However, the pathogenesis of COPD is not completely elucidated, and it is the long-term interaction of many factors including environmental factors and genetic factors [7].…”

Section: Introductionmentioning

confidence: 99%

The association between cystatin C and COPD: a meta-analysis and systematic review

et al. 2020

View full text Add to dashboard Cite

Background: In recent years, many studies have discovered that cystatin C (Cys C) may play an important role in respiratory diseases, especially in chronic obstructive pulmonary disease (COPD). However, the findings of these studies were inconsistent. This systematic review and meta-analysis aimed to assess the relationship between serum Cys C and COPD. Methods: We conducted a systematic literature search in PubMed, Embase, Web of Science, Wanfang databases, and the China National Knowledge Infrastructure. The standardized mean difference (SMD), Fisher's Z-value and 95% confidence interval (CI) were calculated to investigate the effect sizes. Subgroup analyses were performed on disease status, ethnicity, assay method, and study design. Sensitivity was performed, and publication bias was assessed. Results: A total of 15 studies, including 4079 COPD patients and 5949 controls, were included in this meta-analysis. The results showed that serum Cys C levels in patients with COPD were significantly higher than those in controls (SMD = 0.99, 95% CI =0.62-1.37, P < 0.001), especially in AECOPD (SMD = 1.59, 95% CI =1.05-2.13, P < 0.001), and there were statistically different among AECOPD and SCOPD (SMD = 0.35, 95% CI =0.10-0.59, P = 0.005). The serum Cys C levels were negatively correlated with FEV1%pre (Z = − 0.45, 95%CI =-0.58-0.32, P = 0.011) and FEV1/FVC (Z = − 0.32, 95%CI =-0.50-0.14, P = 0.006). The serum Cys C levels were independent of ethnicity, assay method, and study design. Conclusion: Serum Cys C levels were associated with COPD and COPD exacerbation, and they were inversely correlated with FEV1%pre and FEV1/FVC.

show abstract

Diagnosis, Prevention and Treatment of Stable COPD and Acute Exacerbations of COPD: The Swiss Recommendations 2018

Cited by 33 publications

References 101 publications

Systematic Review of Pain in Clinical Practice Guidelines for Management of COPD: A Case for Including Chronic Pain?

Systematic Review of Pain in Clinical Practice Guidelines for Management of COPD: A Case for Including Chronic Pain?

Suppression of Rcn3 in the alveolar epithelial cells may have beneficial effect against COPD

The association between cystatin C and COPD: a meta-analysis and systematic review

Contact Info

Product

Resources

About